SCHEMBL25344388

SCHEMBL25344388

Fc1cnc(-n2ncc3c(Cl)ncnc32)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.38
TP53 P04637 8/20 0.38
SLC2A1 P11166 2/20 0.37
SLC2A2 P11168 2/20 0.37
SLC2A3 P11169 2/20 0.37
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP17A1 P05093 1/20 0.35
LMNA P02545 3/20 0.35
POLB P06746 1/20 0.35
XDH P47989 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25345417 0.83 TP53 (0.38) MAPTTP53SLC2A1SLC2A2SLC2A3
SCHEMBL25343558 0.82 GRM1 (0.32) SMN1; SMN2CYP17A1POLB
SCHEMBL25342542 0.79 TP53 (0.38) MAPTTP53SLC2A1SLC2A2SLC2A3
SCHEMBL839701 0.79 CYP17A1 (0.53) MAPTTP53SLC2A1SLC2A2SLC2A3
SCHEMBL30568414 0.79 CYP17A1 (0.53) MAPTTP53SLC2A1SLC2A2SLC2A3
SCHEMBL839516 0.77 XDH (0.38) MAPTTP53HPGDSMN1; SMN2KDM4E
SCHEMBL25342907 0.77 CYP17A1 (0.43) MAPTTP53SLC2A1SLC2A2SLC2A3
SCHEMBL13387475 0.75 TP53 (0.59) MAPTTP53HPGDSMN1; SMN2KDM4E
SCHEMBL25344682 0.74 SLC2A1 (0.42) MAPTTP53SLC2A1SLC2A2SLC2A3
SCHEMBL25342469 0.74 SLC2A1 (0.43) MAPTTP53SLC2A1SLC2A2SLC2A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472739-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2024-12-11 EP disclosed
WO-2023148129-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-08-10 WO disclosed